The popularity of Sildenafil initially fueled a surge for major pharmaceutical companies, however recent shifts present a murky scenario for investors. Generic alternatives are eroding profits, and ongoing patent https://alberttuit153433.blogaritma.com/39071102/sildenafil-and-pharma-a-risky-investment